文献速递支持与姑息治疗

从预测到精准:个体化免疫检查点阻断治疗的生物标志物发现与预测建模

From prediction to precision: Biomarker discovery and predictive modeling for personalized immune checkpoint blockade therapy.
PubMed 文献 · Eur J Cancer · 2026-03-30

免疫检查点阻断(ICB)应答率因瘤种差异大且部分患者不获益,现有基线生物标志物准确性及泛化性不足。单细胞与空间转录组等高分辨技术可揭示肿瘤微环境交互,支持新标志物与靶点发现。本文综述ICB生物标志物现状、识别技术及多模态计算建模,并讨论新辅助精准免疫治疗前景。

要点

  • 现有基线ICB生物标志物准确性及跨瘤种泛化性有限。
  • 单细胞与空间转录组可高分辨解析肿瘤微环境驱动应答与毒性。
  • 整合分子图谱与预测建模有望推进新辅助精准免疫治疗。

核心结论

  • 将分子图谱与预测建模整合,有望推进个体化精准免疫治疗并最大化应答、减少毒性。

研究设计与样本

  • 本文为综述,讨论ICB生物标志物现状、识别所依据的图谱技术及多模态计算建模方法。

主要发现

  • ICB应答率在不同瘤种间差异大,相当比例患者不获益。
  • 单细胞与空间转录组可高分辨分析肿瘤微环境,揭示驱动治疗敏感、耐药及免疫相关不良事件的肿瘤-免疫细胞交互。

临床怎么用

  • 可利用单细胞与空间转录组等高分辨图谱技术辅助发现新生物标志物与治疗靶点。
  • 可探索整合多模态分子图谱与预测建模以预测ICB应答与毒性。
  • 在新辅助治疗场景中可考虑将分子图谱与预测建模结合以推进精准免疫治疗。

局限性

  • 现有基线生物标志物中,能在不同瘤种间提供足够准确性与泛化性的较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint blockers have revolutionized cancer therapy, offering a promising treatment option for various malignancies. However, response rates vary widely across cancer types, and a significant proportion of patients do not benefit from this therapy. While numerous clinical and molecular biomarkers have been proposed to predict response at baseline, few offer sufficient accuracy and generalizability across tumor types. Advances in molecular profiling, particularly single-cell and spatial transcriptomics, now enable high-resolution analysis of the tumor microenvironment, revealing interactions between tumor and immune cells that drive therapy sensitivity, resistance, and immune-related adverse events. These technologies provide unprecedented insight into the cellular and molecular dynamics of tumors and their surrounding cells and could support the discovery of novel biomarkers and therapeutic targets. In this review, we discuss the current landscape of ICB biomarkers, the profiling techniques underlying their identification, and computational methods that drive biomarker discovery and integration across multiple modalities to predict therapy response and toxicity. Finally, we discuss how the incorporation of molecular profiling with predictive modeling holds great promise for advancing precision immunotherapy in the neoadjuvant setting. Ultimately, the goal is to deliver tailored treatment strategies that maximize response and minimize harmful side effects.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Wijnen SCMA, Dimitriadis P, Wessels LFA, et al. From prediction to precision: Biomarker discovery and predictive modeling for personalized immune checkpoint blockade therapy. Eur J Cancer. 2026. PMID: 41930857. doi:10.1016/j.ejca.2026.116711

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。